Talus Bioscience, Inc.
Talus Bio is a biotechnology company focused on revealing and modulating the regulome, the body's control center for gene expression. Their proprietary platform measures and modulates the regulome in its native context, unlocking the ability to design interventions at the root of cellular decision making. The company develops multiple first-in-class programs targeting previously undruggable targets, spanning oncology, rare disease, and immune dysfunction. Talus Bio collaborates with innovative partners to discover molecules, targets, and biomarkers, and to accelerate preclinical development.
Industries
Nr. of Employees
small (1-50)
Products
Integrated regulome screening platform
An integrated, automated platform combining live-cell functional proteomics, high-throughput mass spectrometry, and AI models to measure and perturb gene-regulatory proteins and generate large-scale compound-target datasets.
Integrated regulome screening platform
An integrated, automated platform combining live-cell functional proteomics, high-throughput mass spectrometry, and AI models to measure and perturb gene-regulatory proteins and generate large-scale compound-target datasets.
Services
Discovery service that identifies disease-associated regulatory proteins and candidate biomarkers using live-cell functional proteomics and high-throughput screening.
Provision of large-scale cell-based screening and compound-target interaction datasets to support hit discovery and AI model development.
Analytical and computational services to deconvolve mechanism of action and predict toxicity to inform preclinical candidate selection.
Development and deployment of proteomics data-analysis pipelines, spectral library generation, and ML models for peptide sequencing and sensitive spectral searching.
Discovery service that identifies disease-associated regulatory proteins and candidate biomarkers using live-cell functional proteomics and high-throughput screening.
Provision of large-scale cell-based screening and compound-target interaction datasets to support hit discovery and AI model development.
Analytical and computational services to deconvolve mechanism of action and predict toxicity to inform preclinical candidate selection.
Development and deployment of proteomics data-analysis pipelines, spectral library generation, and ML models for peptide sequencing and sensitive spectral searching.
Expertise Areas
- Regulome-focused functional proteomics
- Transcription factor and nuclear protein drug discovery
- High-throughput cell-based screening
- Computational proteomics and ML for mass spectrometry
Key Technologies
- Functional proteomics
- High-throughput mass spectrometry (DIA-capable workflows)
- Automated proteomics sample preparation
- High-throughput cell-based assays
News & Updates
Presentation of preclinical data on transcription factor therapeutics at AACR 2025.
Announcement of new VP of Business Development to enhance collaborations and partnerships.
Launch of a new blog series focusing on targeting previously undruggable proteins.
A publication on creating spectral libraries from data-independent acquisition mass spectrometry.
Research on peptide sequencing using transformer models in mass spectrometry.
Introduction of an open-source pipeline for proteomics data analysis.
Presentation of preclinical data on transcription factor therapeutics at AACR 2025.
Announcement of new VP of Business Development to enhance collaborations and partnerships.
Launch of a new blog series focusing on targeting previously undruggable proteins.
A publication on creating spectral libraries from data-independent acquisition mass spectrometry.
Research on peptide sequencing using transformer models in mass spectrometry.
Introduction of an open-source pipeline for proteomics data analysis.